Article
Comparison of three doses of enalapril in preventing left ventricular remodeling after acute myocardial infarction in the rat.
Division of Coronary Heart Disease, Cardiovascular Institute & Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing 100037, China.
Chinese medical journal (impact factor:
0.86).
03/2002;
115(3):347-51.
pp.347-51
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial.
[show abstract] [hide abstract]
ABSTRACT: Angiotensin-converting enzyme inhibitors and the angiotensin-receptor blocker valsartan ameliorate ventricular remodeling after myocardial infarction (MI). Based on previous clinical trials, a maximum clinical dose is recommended in practical guidelines. Yet, has not been clearly demonstrated whether the recommended dose is more efficacious compared to the lower dose that is commonly used in clinical practice. Valsartan in post-MI remodeling (VALID) is a randomized, open-label, single-blinded multicenter study designed to compare the efficacy of different clinical dose of valsartan on the post-MI ventricular remodeling. This study also aims to assess neurohormone change and clinical parameters of patients during the post-infarct period. A total of 1116 patients with left ventricular dysfunction following the first episode of acute ST-elevation MI are to be enrolled and randomized to a maximal tolerable dose (up to 320 mg/day) or usual dose (80 mg/day) of valsartan for 12 months in 2:1 ratio. Echocardiographic analysis for quantifying post-MI ventricular remodeling is to be conducted in central core laboratory. Clinical assessment and laboratory test are performed at fixed times. VALID is a multicenter collaborative study to evaluate the impact of dose of valsartan on the post-MI ventricular remodeling. The results of the study provide information about optimal dosing of the drug in the management of patients after MI. The results will be available by 2012. NCT01340326.Trials 11/2011; 12:247. · 2.02 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
149 female SD rats
4 weeks
acute myocardial infarction
AMI control group
complete experimental data
dead rats
direct gastric gavage
four AMI groups
hemodynamic studies
left coronary artery
low dose enalapril
low doses
low-dose enalapril groups
middle-dose enalapril
middle-dose enalapril groups
non-infarction controls
normal rats
pathology analysis
relative weight
three enalapril groups